12th Mai 2022
Neuigkeiten
Bleiben Sie auf dem neuesten Stand. Hier finden Sie unsere Pressemitteilungen. Hier können Sie sich über bevorstehende Veranstaltungen informieren, an denen Curium teilnehmen wird.
3rd Mai 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th April 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th April 2022
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
25th Januar 2022
Curium to become major player in the supply on non carrier added Lu-177
6th Januar 2022
Curium is attending these global congresses in 2022
15th Dezember 2021
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
27th Oktober 2021
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
24th August 2021
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
1st Juni 2021
Curium Acquires Austrian Radiopharmaceuticals Company IASON
5th Mai 2021
RadioMedix & Curium Announce Detectnet™ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
4th Mai 2021
Curium Announces Filing of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
28th April 2021
Curium to Expand Noblesville Facility’s Workforce
23rd März 2021
RadioMedix & Curium Announce Simplified Coding for Detectnet™ (copper Cu 64 dotatate injection)
17th März 2021
A statement on the use of Xenon Xe 133 Gas during the COVID-19 pandemic
2nd März 2021
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
2nd Februar 2021
Curium is attending these global congresses in 2021
26th Januar 2021
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection)
9th Dezember 2020
RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)
8th September 2020